Benzinga··Vandana SinghSanofi Beats Earnings as Dupixent Expansion Into Pediatric Urticaria Broadens Growth
Sanofi's Dupixent gains FDA approval for pediatric urticaria as Q1 earnings beat expectations with 30.8% drug growth at $12.31B sales.
SNYREGNchronic spontaneous urticariaFDA approval